News
-
-
-
-
-
-
-
PRESS RELEASE
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
NanoViricides, Inc. provides details on Phase II Clinical Trial of NV-387 Oral Gummies for treating Bundibugyo Ebolavirus (BDBV) outbreak in DRC. Trial targets optimal dosing regimen and safety signals for Ebola Virus Disease patients -
PRESS RELEASE
Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 6.02 Million Tokens, and Total Crypto and Total Cash & Marketable Securities Holdings of $17.4 Billion
Bitmine Immersion Technologies (BMNR) announces holding 6.02M ETH tokens and $17.4B worth of crypto, cash & securities. Tom Lee to speak at Token2049 in Singapore -
-